BlackRock Health Sciences Trust (BME) NPORT-P BlackRock Health Sciences Trust (Mar 2024 report)

Schedule of Investments (unaudited) March 31, 2024 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Biotechnology — 23.8%
4D Molecular Therapeutics, Inc.(a)		17,173	$	547,132
AbbVie, Inc.		184,866		33,664,099
AC Immune SA(a)		78,180		231,413
Alnylam Pharmaceuticals, Inc.(a)		24,255		3,624,910
Amgen, Inc.(b)		75,441		21,449,385
Argenx SE, ADR(a)		15,123		5,954,228
Autolus Therapeutics PLC, ADR(a)		64,258		409,966
Beam Therapeutics, Inc.(a)		9,264		306,083
BeiGene Ltd., ADR(a)		6,675		1,043,903
Biogen, Inc.(a)		42,571		9,179,585
BioMarin Pharmaceutical, Inc.(a)		45,161		3,944,362
Blueprint Medicines Corp.(a)		26,672		2,530,106
Bridgebio Pharma, Inc.(a)		16,735		517,446
Cabaletta Bio, Inc.(a)		29,605		505,061
CG oncology, Inc.(a)		19,778		868,254
CureVac NV(a)		29,850		90,446
Denali Therapeutics, Inc.(a)		30,843		632,898
Dyne Therapeutics, Inc.(a)		11,606		329,494
Exact Sciences Corp.(a)		19,226		1,327,748
Genmab A/S(a)		2,927		877,598
Genmab A/S, ADR(a)		19,943		596,495
Gilead Sciences, Inc.		111,030		8,132,947
Immatics NV(a)		21,538		226,364
Immunocore Holdings PLC, ADR(a)		12,497		812,305
Incyte Corp.(a)		15,306		871,983
Insmed, Inc.(a)		16,685		452,664
Ionis Pharmaceuticals, Inc.(a)		18,725		811,729
Kyverna Therapeutics, Inc.(a)		9,645		239,582
Legend Biotech Corp., ADR(a)		32,098		1,800,377
Merus NV(a)		22,655		1,020,155
Moderna, Inc.(a)		33,556		3,575,727
MoonLake Immunotherapeutics, Class A(a)		10,337		519,228
Morphic Holding, Inc.(a)		7,827		275,510
Neurocrine Biosciences, Inc.(a)		9,808		1,352,719
Neurogene, Inc.(a)		19,342		984,508
Nuvalent, Inc., Class A(a)		13,886		1,042,700
Prime Medicine, Inc.(a)		22,929		160,503
Protagonist Therapeutics, Inc.(a)		27,836		805,295
PTC Therapeutics, Inc.(a)		19,817		576,477
Regeneron Pharmaceuticals, Inc.(a)		9,307		8,957,894
REVOLUTION Medicines, Inc.(a)		19,714		635,382
Rhythm Pharmaceuticals, Inc.(a)		49,466		2,143,362
Rocket Pharmaceuticals, Inc.(a)		18,343		494,160
Roivant Sciences Ltd.(a)		57,525		606,314
Sage Therapeutics, Inc.(a)		13,650		255,801
Sagimet Biosciences, Inc., Series A(a)		21,965		119,050
Sarepta Therapeutics, Inc.(a)		22,338		2,891,877
Stoke Therapeutics, Inc.(a)		65,255		880,942
Tenaya Therapeutics, Inc.(a)		58,697		306,985
Ultragenyx Pharmaceutical, Inc.(a)		14,268		666,173
Vaxcyte, Inc.(a)		28,905		1,974,501
Vertex Pharmaceuticals, Inc.(a)		26,679		11,152,089
Viking Therapeutics, Inc.(a)		25,612		2,100,184
Voyager Therapeutics, Inc.(a)		32,205		299,829
Xenon Pharmaceuticals, Inc.(a)		32,241		1,387,975
Zealand Pharma A/S(a)		4,395		435,324
				147,599,227

Security	Shares		Value
Capital Markets — 0.1%
Helix Acquisition Corp. II, Class A(a)		61,530	$	636,835
Health Care Equipment & Supplies — 24.6%
Abbott Laboratories(b)		190,037		21,599,605
Alcon, Inc.		54,365		4,528,061
Align Technology, Inc.(a)		11,220		3,679,262
Baxter International, Inc.		60,439		2,583,163
Becton Dickinson & Co.		39,171		9,692,864
Boston Scientific Corp.(a)		442,429		30,301,962
Cooper Cos., Inc.		60,763		6,165,014
Dexcom, Inc.(a)		46,293		6,420,839
Edwards Lifesciences Corp.(a)		75,800		7,243,448
Envista Holdings Corp.(a)		22,246		475,620
GE HealthCare Technologies, Inc.(a)		42,353		3,850,311
Glaukos Corp.(a)		5,240		494,080
IDEXX Laboratories, Inc.(a)		7,516		4,058,114
Inspire Medical Systems, Inc.(a)		5,782		1,241,916
Intuitive Surgical, Inc.(a)		43,715		17,446,219
Masimo Corp.(a)		15,144		2,223,896
Medtronic PLC		79,846		6,958,579
Novocure Ltd.(a)		29,303		458,006
Orchestra BioMed Holdings, Inc.(a)		18,076		95,261
Penumbra, Inc.(a)		12,105		2,701,594
Shockwave Medical, Inc.(a)		3,150		1,025,735
STERIS PLC		9,642		2,167,714
Stryker Corp.		49,107		17,573,922
				152,985,185
Health Care Providers & Services — 20.8%
Cencora, Inc.		62,148		15,101,342
Centene Corp.(a)		87,074		6,833,567
Cigna Group		31,736		11,526,198
Elevance Health, Inc.(b)		30,102		15,609,091
Guardant Health, Inc.(a)		15,095		311,410
HCA Healthcare, Inc.		21,723		7,245,272
Humana, Inc.		14,550		5,044,776
Laboratory Corp. of America Holdings		6,745		1,473,513
McKesson Corp.		25,023		13,433,597
Quest Diagnostics, Inc.		11,479		1,527,970
UnitedHealth Group, Inc.(b)		103,608		51,254,878
				129,361,614
Health Care Technology — 0.0%
Carbon Health(a)(c)		65		66,179
Life Sciences Tools & Services — 8.3%
10X Genomics, Inc., Class A(a)		15,123		567,566
Agilent Technologies, Inc.		23,561		3,428,361
Avantor, Inc.(a)		55,614		1,422,050
Bio-Techne Corp.		16,718		1,176,780
Danaher Corp.		78,006		19,479,658
IQVIA Holdings, Inc.(a)		12,013		3,037,968
Mettler-Toledo International, Inc.(a)		1,170		1,557,609
Nautilus Biotechnology, Inc.(a)		16,560		48,687
QIAGEN NV		35,078		1,508,003
Rapid Micro Biosystems, Inc., Class A(a)		20,561		19,944
Repligen Corp.(a)		8,125		1,494,350
Thermo Fisher Scientific, Inc.		24,009		13,954,271
West Pharmaceutical Services, Inc.		10,207		4,039,012
				51,734,259
Pharmaceuticals — 20.7%
AstraZeneca PLC		24,269		3,260,389

SCHEDULE  OF INVESTMENTS 1

Schedule of Investments (unaudited) (continued) March 31, 2024 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets)

Security	Shares		Value
Pharmaceuticals (continued)
Daiichi Sankyo Co. Ltd.		34,800	$	1,107,297
Elanco Animal Health, Inc.(a)		97,264		1,583,458
Eli Lilly & Co.		79,277		61,674,335
Johnson & Johnson(b)		70,368		11,131,514
Longboard Pharmaceuticals, Inc.(a)		2,931		63,310
Merck & Co., Inc.(b)		218,212		28,793,073
Novo Nordisk A/S, Class B		47,689		6,117,228
Pfizer, Inc.(b)		282,816		7,848,144
Sanofi SA		26,788		2,606,055
Structure Therapeutics, Inc., ADR(a)		26,914		1,153,534
Zoetis, Inc., Class A		20,979		3,549,857
				128,888,194
Total Common Stocks — 98.3% (Cost: $382,059,970)				611,271,493
	Benefical Interest (000)
Other Interests
Biotechnology — 0.0%
Affinivax, Inc., (Acquired 08/18/22, Cost: $ —)(c)(d)(e)	$	6		86,988
Health Care Providers & Services — 0.0%
Afferent Pharmaceuticals, Inc., (Acquired 09/30/15, Cost: $ —)(c)(d)(e)		190		26,622
Total Other Interests — 0.0% (Cost: $ —)				113,610
	Shares
Preferred Securities
Preferred Stocks — 0.7%(a)(c)(e)
Biotechnology — 0.3%
Adarx Pharamaceuticals, Series C, (Acquired 08/02/23, Cost: $440,003)		52,885		440,003
Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $265,002)		44,167		145,309
Genesis Therapeutics, Series B, (Acquired 08/10/23, Cost: $292,001)		57,170		287,565
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $224,200)		190,000		68,400
Kartos Therapeutics, Series C, (Acquired 08/22/23, Cost: $485,124)		85,817		520,909
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $590,800)		21,100		590,800
				2,052,986
Health Care Equipment & Supplies — 0.2%
Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: $595,999)		101,741		293,014
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $1,070,001)		367,395		804,595
Swift Health Systems, Inc., Series D, (Acquired 08/27/21, Cost: $286,998)		92,580		20
				1,097,629

Security	Shares		Value
Health Care Providers & Services — 0.0%
Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $515,759)		4,243,029	$	283,833
Health Care Technology — 0.1%
Carbon Health Technologies, Inc., Series D2, (Acquired 02/02/23, Cost: $907,000)		89,892		302,037
Pharmaceuticals — 0.1%
Insitro, Inc., Series C, (Acquired 03/10/21, Cost: $560,000)		30,616		345,042
				4,081,527
Total Preferred Securities — 0.7% (Cost: $6,232,887)				4,081,527
Rights
Biotechnology — 0.0%
Korro Bio, Inc., CVR(c)		15,747		11,023
Korro Bio, Inc., CVR		28,060		382
				11,405
Health Care Equipment & Supplies — 0.0%
Abiomed, Inc., CVR(c)		14,359		41,067
Total Rights — 0.0% (Cost: $25,669)				52,472
Warrants
Health Care Providers & Services — 0.0%
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 08/06/26, Strike Price USD 11.50)(a)		4,201		72
Pharmaceuticals — 0.0%
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)(a)		4,050		1,225
Total Warrants — 0.0% (Cost: $14,030)				1,297
Total Long-Term Investments — 99.0% (Cost: $388,332,556)				615,520,399
Short-Term Securities
Money Market Funds — 2.4%
BlackRock Cash Funds: Institutional, SL Agency Shares, 5.50%(f)(g)(h)		1,343,068		1,343,605
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.19%(f)(g)		13,687,033		13,687,033
Total Short-Term Securities — 2.4% (Cost: $15,030,773)				15,030,638
Total Investments Before Options Written — 101.4% (Cost: $403,363,329)				630,551,037
Options Written — (1.1)% (Premiums Received: $(6,859,904))				(7,058,820	)
Total Investments, Net of Options Written — 100.3% (Cost: $396,503,425)				623,492,217
Liabilities in Excess of Other Assets — (0.3)%				(1,935,730	)
Net Assets — 100.0%			$	621,556,487

2

Schedule of Investments (unaudited) (continued) March 31, 2024 BlackRock Health Sciences Trust (BME)

^(a)  Non-income producing security.

^(b)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(c)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(d)  Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.

^(e)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $4,195,137, representing 0.7% of its net assets as of period end, and an original cost of $6,232,887.

^(f)  Affiliate of the Trust.

^(g)  Annualized 7-day yield as of period end.

^(h)  All or a portion of this security was purchased with the cash collateral from loaned securities.

For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the period ended March 31, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/23		Purchases at Cost			Proceeds from Sales			Net Realized Gain (Loss)			Change in Unrealized Appreciation (Depreciation)			Value at 03/31/24		Shares Held at 03/31/24		Income			Capital Gain Distributions from Underlying Funds
BlackRock Cash Funds: Institutional, SL Agency Shares	$	—	$	1,343,740	(a)	$	—		$	—		$	(135	)	$	1,343,605		1,343,068	$	—		$	—
BlackRock Liquidity Funds, T-Fund, Institutional Class		31,396,977		—			(17,709,944	)(a)		—			—			13,687,033		13,687,033		272,992			—
SL Liquidity Series, LLC, Money Market Series(b)		—		517	(a)		—			(517	)		—			—		—		270	(c)		—
									$	(517	)	$	(135	)	$	15,030,638			$	273,262		$	—

^(a)  Represents net amount purchased (sold).

^(b)  As of period end, the entity is no longer held.

^(c)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price		Notional Amount (000)		Value
Call
Cencora, Inc.		23		04/01/24	USD	218.00	USD	559	$	(57,805	)
Alcon, Inc.		135		04/03/24	USD	81.25	USD	1,124		(30,726	)
Abbott Laboratories		156		04/05/24	USD	123.00	USD	1,773		(390	)
AbbVie, Inc.		204		04/05/24	USD	185.00	USD	3,715		(8,976	)
Align Technology, Inc.		10		04/05/24	USD	320.00	USD	328		(10,700	)
Baxter International, Inc.		101		04/05/24	USD	44.00	USD	432		(758	)
Humana, Inc.		3		04/05/24	USD	380.00	USD	104		(173	)
McKesson Corp.		43		04/05/24	USD	520.00	USD	2,308		(78,690	)
Medtronic PLC		49		04/05/24	USD	87.00	USD	427		(3,773	)
Moderna, Inc.		21		04/05/24	USD	103.00	USD	224		(10,027	)
Pfizer, Inc.		178		04/05/24	USD	28.00	USD	494		(3,916	)
Vertex Pharmaceuticals, Inc.		46		04/05/24	USD	435.00	USD	1,923		(4,600	)
Abbott Laboratories		156		04/12/24	USD	114.00	USD	1,773		(21,840	)
Align Technology, Inc.		11		04/12/24	USD	310.00	USD	361		(21,890	)
Biogen, Inc.		71		04/12/24	USD	230.00	USD	1,531		(6,390	)
Centene Corp.		62		04/12/24	USD	78.00	USD	487		(13,330	)
Cigna Group.		38		04/12/24	USD	345.00	USD	1,380		(75,050	)
Danaher Corp.		111		04/12/24	USD	255.00	USD	2,772		(18,870	)
Dexcom, Inc.		69		04/12/24	USD	140.00	USD	957		(21,562	)
Intuitive Surgical, Inc.		54		04/12/24	USD	395.00	USD	2,155		(47,790	)
Johnson & Johnson		146		04/12/24	USD	165.00	USD	2,310		(1,606	)
Medtronic PLC		59		04/12/24	USD	86.00	USD	514		(10,738	)
10X Genomics, Inc., Class A		28		04/19/24	USD	53.12	USD	105		(163	)
Abbott Laboratories		410		04/19/24	USD	120.00	USD	4,660		(14,555	)
AbbVie, Inc.		90		04/19/24	USD	175.00	USD	1,639		(67,275	)

SCHEDULE  OF INVESTMENTS 3

Schedule of Investments (unaudited) (continued) March 31, 2024 BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price		Notional Amount (000)		Value
Call (continued)
Agilent Technologies, Inc.		44		04/19/24	USD	135.14	USD	640	$	(48,648	)
Alcon, Inc.		143		04/19/24	USD	80.00	USD	1,191		(55,770	)
Align Technology, Inc.		11		04/19/24	USD	310.00	USD	361		(23,430	)
Alnylam Pharmaceuticals, Inc.		67		04/19/24	USD	165.00	USD	1,001		(7,035	)
Amgen, Inc.		166		04/19/24	USD	300.00	USD	4,720		(16,351	)
Argenx SE, ADR		53		04/19/24	USD	430.00	USD	2,087		(20,405	)
Avantor, Inc.		75		04/19/24	USD	23.98	USD	192		(13,840	)
Becton Dickinson & Co.		100		04/19/24	USD	245.00	USD	2,475		(59,500	)
BeiGene Ltd., ADR		13		04/19/24	USD	165.00	USD	203		(4,225	)
BioMarin Pharmaceutical, Inc.		130		04/19/24	USD	90.00	USD	1,135		(13,325	)
Bio-Techne Corp.		23		04/19/24	USD	75.00	USD	162		(6,152	)
Blueprint Medicines Corp.		51		04/19/24	USD	100.00	USD	484		(14,152	)
Bridgebio Pharma, Inc.		33		04/19/24	USD	35.00	USD	102		(4,043	)
Cencora, Inc.		64		04/19/24	USD	234.00	USD	1,555		(68,885	)
Centene Corp.		77		04/19/24	USD	82.50	USD	604		(6,160	)
Cigna Group.		7		04/19/24	USD	340.00	USD	254		(18,025	)
Cooper Cos., Inc.		100		04/19/24	USD	97.50	USD	1,015		(50,000	)
Dexcom, Inc.		53		04/19/24	USD	140.00	USD	735		(21,200	)
Elanco Animal Health, Inc.		138		04/19/24	USD	16.00	USD	225		(9,315	)
Elevance Health, Inc.		54		04/19/24	USD	510.00	USD	2,800		(93,150	)
Eli Lilly & Co.		96		04/19/24	USD	740.00	USD	7,468		(440,400	)
Envista Holdings Corp.		84		04/19/24	USD	22.50	USD	180		(2,100	)
Exact Sciences Corp.		19		04/19/24	USD	65.00	USD	131		(14,630	)
Gilead Sciences, Inc.		170		04/19/24	USD	80.00	USD	1,245		(1,275	)
Guardant Health, Inc.		29		04/19/24	USD	22.50	USD	60		(3,045	)
HCA Healthcare, Inc.		41		04/19/24	USD	310.00	USD	1,367		(104,550	)
Humana, Inc.		31		04/19/24	USD	355.00	USD	1,075		(22,940	)
Immunocore Holdings PLC, ADR		18		04/19/24	USD	71.75	USD	117		(3,284	)
Immunocore Holdings PLC, ADR		29		04/19/24	USD	65.00	USD	189		(6,235	)
Incyte Corp.		37		04/19/24	USD	62.50	USD	211		(463	)
Intuitive Surgical, Inc.		54		04/19/24	USD	390.00	USD	2,155		(106,920	)
IQVIA Holdings, Inc.		34		04/19/24	USD	260.00	USD	860		(7,735	)
Johnson & Johnson		61		04/19/24	USD	160.00	USD	965		(11,071	)
Laboratory Corp. of America Holdings		25		04/19/24	USD	228.25	USD	546		(3,030	)
Legend Biotech Corp., ADR		61		04/19/24	USD	65.00	USD	342		(5,490	)
Masimo Corp.		16		04/19/24	USD	140.00	USD	235		(13,520	)
Masimo Corp.		9		04/19/24	USD	135.00	USD	132		(11,790	)
Merck & Co., Inc.		278		04/19/24	USD	125.00	USD	3,668		(208,500	)
Mettler-Toledo International, Inc.		1		04/19/24	USD	1,340.00	USD	133		(2,845	)
Moderna, Inc.		31		04/19/24	USD	105.00	USD	330		(17,437	)
MoonLake Immunotherapeutics, Class A		20		04/19/24	USD	55.00	USD	100		(3,850	)
Neurocrine Biosciences, Inc.		15		04/19/24	USD	140.00	USD	207		(4,950	)
Nuvalent, Inc., Class A		26		04/19/24	USD	85.00	USD	195		(5,720	)
Penumbra, Inc.		45		04/19/24	USD	280.00	USD	1,004		(7,425	)
Pfizer, Inc.		537		04/19/24	USD	29.00	USD	1,490		(10,203	)
PTC Therapeutics, Inc.		75		04/19/24	USD	31.00	USD	218		(9,375	)
QIAGEN NV		65		04/19/24	USD	45.00	USD	279		(6,500	)
Regeneron Pharmaceuticals, Inc.		25		04/19/24	USD	970.00	USD	2,406		(42,375	)
Repligen Corp.		30		04/19/24	USD	206.00	USD	552		(2,383	)
REVOLUTION Medicines, Inc.		35		04/19/24	USD	32.00	USD	113		(4,813	)
REVOLUTION Medicines, Inc.		34		04/19/24	USD	34.00	USD	110		(3,655	)
Rhythm Pharmaceuticals, Inc.		89		04/19/24	USD	51.50	USD	386		(4,692	)
Rhythm Pharmaceuticals, Inc.		21		04/19/24	USD	45.00	USD	91		(3,518	)
Rocket Pharmaceuticals, Inc.		37		04/19/24	USD	30.00	USD	100		(1,203	)
Shockwave Medical, Inc.		6		04/19/24	USD	260.00	USD	195		(40,080	)
STERIS PLC		19		04/19/24	USD	240.00	USD	427		(1,663	)
Structure Therapeutics Inc., ADR		50		04/19/24	USD	55.00	USD	214		(1,500	)
Stryker Corp.		60		04/19/24	USD	342.75	USD	2,147		(111,699	)
Thermo Fisher Scientific, Inc.		28		04/19/24	USD	570.00	USD	1,627		(52,920	)
Thermo Fisher Scientific, Inc.		14		04/19/24	USD	600.00	USD	814		(5,740	)
Ultragenyx Pharmaceutical, Inc.		42		04/19/24	USD	50.00	USD	196		(13,965	)
UnitedHealth Group, Inc.		153		04/19/24	USD	510.00	USD	7,569		(91,800	)

4

Schedule of Investments (unaudited) (continued) March 31, 2024 BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price		Notional Amount (000)		Value
Call (continued)
Vaxcyte, Inc.		109		04/19/24	USD	75.00	USD	745	$	(7,085	)
Vertex Pharmaceuticals, Inc.		55		04/19/24	USD	420.00	USD	2,299		(47,850	)
Viking Therapeutics, Inc.		32		04/19/24	USD	31.00	USD	262		(162,240	)
West Pharmaceutical Services, Inc.		1		04/19/24	USD	380.00	USD	40		(1,975	)
Xenon Pharmaceuticals Inc.		58		04/19/24	USD	55.00	USD	250		(14,645	)
Zoetis, Inc.		79		04/19/24	USD	200.00	USD	1,337		(1,383	)
Align Technology, Inc.		10		04/26/24	USD	330.00	USD	328		(20,500	)
Amgen, Inc.		110		04/26/24	USD	280.00	USD	3,128		(105,050	)
Baxter International, Inc.		13		04/26/24	USD	42.00	USD	56		(2,990	)
Biogen, Inc.		23		04/26/24	USD	220.00	USD	496		(14,720	)
Bridgebio Pharma, Inc.		30		04/26/24	USD	31.00	USD	93		(7,650	)
Centene Corp.		96		04/26/24	USD	82.00	USD	753		(15,120	)
Danaher Corp.		107		04/26/24	USD	265.00	USD	2,672		(16,317	)
Dexcom, Inc.		53		04/26/24	USD	143.00	USD	735		(26,235	)
Eli Lilly & Co.		64		04/26/24	USD	810.00	USD	4,979		(77,760	)
Gilead Sciences, Inc.		211		04/26/24	USD	75.00	USD	1,546		(23,421	)
Johnson & Johnson		60		04/26/24	USD	160.00	USD	949		(13,380	)
McKesson Corp.		14		04/26/24	USD	545.00	USD	752		(10,220	)
Medtronic PLC		59		04/26/24	USD	86.00	USD	514		(14,543	)
Merck & Co., Inc.		273		04/26/24	USD	123.00	USD	3,602		(273,000	)
Moderna, Inc.		37		04/26/24	USD	113.00	USD	394		(11,655	)
Pfizer, Inc.		359		04/26/24	USD	29.00	USD	996		(9,693	)
Thermo Fisher Scientific, Inc.		14		04/26/24	USD	600.00	USD	814		(8,890	)
UnitedHealth Group, Inc.		120		04/26/24	USD	505.00	USD	5,936		(103,200	)
AbbVie, Inc.		204		05/03/24	USD	185.00	USD	3,715		(75,480	)
Amgen, Inc.		10		05/03/24	USD	290.00	USD	284		(7,050	)
Baxter International, Inc.		14		05/03/24	USD	42.66	USD	60		(2,826	)
Biogen, Inc.		67		05/03/24	USD	220.00	USD	1,445		(43,550	)
Centene Corp.		95		05/03/24	USD	84.00	USD	746		(9,737	)
Cigna Group.		36		05/03/24	USD	380.00	USD	1,307		(20,340	)
Danaher Corp.		78		05/03/24	USD	255.00	USD	1,948		(42,900	)
Gilead Sciences, Inc.		40		05/03/24	USD	75.00	USD	293		(5,880	)
Humana, Inc.		21		05/03/24	USD	360.00	USD	728		(21,105	)
Intuitive Surgical, Inc.		58		05/03/24	USD	415.00	USD	2,315		(51,040	)
McKesson Corp.		38		05/03/24	USD	545.00	USD	2,040		(33,060	)
Medtronic PLC		68		05/03/24	USD	85.00	USD	593		(21,828	)
Regeneron Pharmaceuticals, Inc.		10		05/03/24	USD	1,010.00	USD	962		(13,150	)
Sarepta Therapeutics, Inc.		33		05/03/24	USD	138.00	USD	427		(18,645	)
Thermo Fisher Scientific, Inc.		35		05/03/24	USD	600.00	USD	2,034		(34,300	)
Baxter International, Inc.		50		05/10/24	USD	43.41	USD	214		(10,520	)
10X Genomics, Inc., Class A		28		05/17/24	USD	45.00	USD	105		(3,010	)
AbbVie, Inc.		204		05/17/24	USD	185.00	USD	3,715		(80,070	)
Agilent Technologies, Inc.		45		05/17/24	USD	150.00	USD	655		(15,975	)
Alcon, Inc.		28		05/17/24	USD	90.00	USD	233		(2,380	)
Alnylam Pharmaceuticals, Inc.		25		05/17/24	USD	165.00	USD	374		(9,250	)
Argenx SE, ADR		9		05/17/24	USD	410.00	USD	354		(15,840	)
Avantor, Inc.		144		05/17/24	USD	26.00	USD	368		(14,040	)
Baxter International, Inc.		50		05/17/24	USD	45.00	USD	214		(4,750	)
Beam Therapeutics, Inc.		23		05/17/24	USD	40.00	USD	76		(3,450	)
Becton Dickinson & Co.		48		05/17/24	USD	245.00	USD	1,188		(47,040	)
BeiGene Ltd., ADR		12		05/17/24	USD	180.00	USD	188		(4,800	)
BioMarin Pharmaceutical, Inc.		41		05/17/24	USD	86.59	USD	358		(18,246	)
Blueprint Medicines Corp.		50		05/17/24	USD	90.00	USD	474		(52,000	)
Boston Scientific Corp.		1,682		05/17/24	USD	67.50	USD	11,520		(491,985	)
Cabaletta Bio, Inc.		60		05/17/24	USD	25.00	USD	102		(5,850	)
Cencora, Inc.		97		05/17/24	USD	240.00	USD	2,357		(86,330	)
Cigna Group		39		05/17/24	USD	350.00	USD	1,416		(86,580	)
Cooper Cos., Inc.		130		05/17/24	USD	105.00	USD	1,319		(19,825	)
Edwards Lifesciences Corp.		213		05/17/24	USD	95.00	USD	2,035		(103,305	)
Elevance Health, Inc.		50		05/17/24	USD	520.00	USD	2,593		(86,000	)
Eli Lilly & Co.		141		05/17/24	USD	800.00	USD	10,969		(421,237	)
Exact Sciences Corp.		37		05/17/24	USD	67.50	USD	256		(29,045	)

SCHEDULE  OF INVESTMENTS 5

Schedule of Investments (unaudited) (continued) March 31, 2024 BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price		Notional Amount (000)		Value
Call (continued)
GE HealthCare Technologies, Inc.		160		05/17/24	USD	90.00	USD	1,455	$	(72,000	)
HCA Healthcare, Inc.		41		05/17/24	USD	325.00	USD	1,367		(80,770	)
IDEXX Laboratories, Inc.		28		05/17/24	USD	560.00	USD	1,512		(42,420	)
Incyte Corp.		21		05/17/24	USD	61.15	USD	120		(2,068	)
Inspire Medical Systems, Inc.		11		05/17/24	USD	210.00	USD	236		(29,260	)
Ionis Pharmaceuticals, Inc.		62		05/17/24	USD	45.00	USD	269		(10,540	)
Legend Biotech Corp., ADR		60		05/17/24	USD	70.00	USD	337		(5,850	)
Masimo Corp.		32		05/17/24	USD	140.00	USD	470		(42,720	)
Medtronic PLC		68		05/17/24	USD	85.00	USD	593		(26,010	)
Merck & Co., Inc.		278		05/17/24	USD	130.00	USD	3,668		(143,865	)
Mettler-Toledo International, Inc.		1		05/17/24	USD	1,340.00	USD	133		(5,410	)
Moderna, Inc.		38		05/17/24	USD	115.00	USD	405		(19,475	)
MoonLake Immunotherapeutics, Class A		19		05/17/24	USD	55.00	USD	95		(6,507	)
Neurocrine Biosciences, Inc.		22		05/17/24	USD	145.00	USD	303		(9,900	)
Nuvalent, Inc., Class A		26		05/17/24	USD	87.65	USD	195		(4,555	)
QIAGEN NV		68		05/17/24	USD	45.00	USD	292		(11,900	)
Quest Diagnostics, Inc.		43		05/17/24	USD	130.00	USD	572		(26,875	)
Rhythm Pharmaceuticals, Inc.		42		05/17/24	USD	50.00	USD	182		(7,455	)
Rocket Pharmaceuticals, Inc.		32		05/17/24	USD	30.00	USD	86		(3,760	)
Shockwave Medical, Inc.		6		05/17/24	USD	270.00	USD	195		(36,240	)
Structure Therapeutics Inc., ADR		52		05/17/24	USD	39.44	USD	223		(40,734	)
Stryker Corp.		126		05/17/24	USD	360.00	USD	4,509		(139,230	)
Ultragenyx Pharmaceutical, Inc.		12		05/17/24	USD	55.00	USD	56		(2,580	)
UnitedHealth Group, Inc.		120		05/17/24	USD	490.00	USD	5,936		(243,300	)
West Pharmaceutical Services, Inc.		37		05/17/24	USD	400.00	USD	1,464		(64,195	)
Xenon Pharmaceuticals Inc.		64		05/17/24	USD	45.00	USD	276		(14,400	)
Elevance Health, Inc.		10		06/21/24	USD	530.00	USD	519		(16,550	)
									$	(6,613,003	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
AstraZeneca PLC	UBS AG		2,500		04/03/24		GBP	99.25		GBP	266	$	(24,071	)
Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		1,800		04/09/24		DKK	829.77		DKK	1,596		(14,289	)
Edwards Lifesciences Corp.	Citibank N.A.		6,400		04/10/24		USD	88.53		USD	612		(48,236	)
Daiichi Sankyo Co. Ltd.	Citibank N.A.		13,200		04/16/24		JPY	5,290.08		JPY	63,581		(2,244	)
AstraZeneca PLC	Morgan Stanley & Co. International PLC		3,350		04/24/24		GBP	104.21		GBP	357		(17,442	)
Cabaletta Bio, Inc.	Barclays Bank PLC		2,600		04/24/24		USD	24.60		USD	44		(1,195	)
Genmab A/S	Morgan Stanley & Co. International PLC		1,100		04/24/24		DKK	2,028.28		DKK	2,280		(16,395	)
Novo Nordisk A/S, Class B	Bank of America N.A.		1,100		04/24/24		DKK	880.65		DKK	976		(4,265	)
Sanofi SA	Morgan Stanley & Co. International PLC		5,400		04/24/24		EUR	89.75		EUR	487		(14,719	)
Elanco Animal Health, Inc.	Goldman Sachs International		9,200		04/30/24		USD	16.53		USD	150		(4,657	)
Inspire Medical Systems, Inc.	Citibank N.A.		1,000		04/30/24		USD	201.57		USD	215		(26,946	)
STERIS PLC	Bank of America N.A.		1,700		04/30/24		USD	234.09		USD	382		(5,063	)
AstraZeneca PLC	UBS AG		3,350		05/02/24		GBP	104.76		GBP	357		(17,741	)
Zealand Pharma A/S	Goldman Sachs International		1,600		05/02/24		DKK	726.59		DKK	1,096		(9,907	)
Genmab A/S, ADR	BNP Paribas SA		7,500		05/06/24		USD	30.64		USD	224		(9,696	)
Cabaletta Bio, Inc.	Barclays Bank PLC		2,600		05/07/24		USD	24.32		USD	44		(2,039	)
Elanco Animal Health, Inc.	Barclays Bank PLC		13,900		05/07/24		USD	16.00		USD	226		(15,077	)
Novo Nordisk A/S, Class B	JPMorgan Chase Bank N.A.		21,200		05/07/24		DKK	867.46		DKK	18,801		(132,520	)
Sanofi SA	Goldman Sachs International		4,700		05/07/24		EUR	92.50		EUR	424		(9,684	)
Bio-Techne Corp.	JPMorgan Chase Bank N.A.		4,000		05/13/24		USD	71.95		USD	282		(12,295	)
Cencora, Inc.	Citibank N.A.		5,200		05/13/24		USD	236.25		USD	1,264		(57,336	)
												$	(445,817	)

6

Schedule of Investments (unaudited) (continued) March 31, 2024 BlackRock Health Sciences Trust (BME)

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

• Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access;

• Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and

• Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Valuation Committee’s assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds. There may not be a secondary market, and/or there are a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust’s policy regarding valuation of financial instruments, refer to its most recent financial statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1			Level 2			Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Biotechnology	$	146,286,305		$	1,312,922		$	—	$	147,599,227
Capital Markets		636,835			—			—		636,835
Health Care Equipment & Supplies		152,985,185			—			—		152,985,185
Health Care Providers & Services		129,361,614			—			—		129,361,614
Health Care Technology		—			—			66,179		66,179
Life Sciences Tools & Services		51,734,259			—			—		51,734,259
Pharmaceuticals		115,797,225			13,090,969			—		128,888,194
Other Interests		—			—			113,610		113,610
Preferred Securities
Preferred Stocks		—			—			4,081,527		4,081,527
Rights		—			382			52,090		52,472
Warrants		1,297			—			—		1,297
Short-Term Securities
Money Market Funds		15,030,638			—			—		15,030,638
	$	611,833,358		$	14,404,273		$	4,313,406	$	630,551,037
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(6,188,899	)	$	(869,921	)	$	—	$	(7,058,820	)

^(a) Derivative financial instruments are options written. Options written are shown at value.

Currency Abbreviation		Portfolio Abbreviation
DKK	Danish Krone	ADR	American Depositary Receipt
EUR	Euro	CVR	Contingent Value Right
GBP	British Pound
JPY	Japanese Yen
USD	United States Dollar

SCHEDULE  OF INVESTMENTS 7